Semin Thromb Hemost 2018; 44(06): 590-594
DOI: 10.1055/s-0037-1607440
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Alloantibodies in von Willebrand Disease

Massimo Franchini
1   Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy
,
Pier Mannuccio Mannucci
2   Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico and University of Milan, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
17 November 2017 (online)

Abstract

von Willebrand disease (VWD), the most commonly known inherited bleeding disorder, is caused by a partial (type 1) or total (type 3) deficiency or dysfunction (type 2) of von Willebrand factor (VWF). Its management encompasses the prevention or treatment of bleeding by raising endogenous VWF levels using a synthetic agent, such as desmopressin, or providing exogenous VWF concentrates. The development of inhibitory alloantibodies against VWF is a rare but often severe complication encountered during the treatment of type 3 VWD, which is associated with a lack of hemostatic response to infused VWF concentrates and more rarely with allergic, even anaphylactic, reactions. This narrative review will focus on the characteristics of such alloantibodies and their management, which can be very challenging for physicians operating at hemophilia treatment centers.

 
  • References

  • 1 von Willebrand EA. Hereditar pseudohemofili. Fin Lakarsallskapets Handl 1926; 67 (07) 7-112
  • 2 Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 2010; 8 (01) 213-216
  • 3 James PD, Goodeve AC. von Willebrand disease. Genet Med 2011; 13 (05) 365-376
  • 4 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69 (02) 454-459
  • 5 Lenting PJ, Casari C, Christophe OD, Denis CV. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost 2012; 10 (12) 2428-2437
  • 6 Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013; 122 (23) 3735-3740
  • 7 Sadler JE, Budde U, Eikenboom JC. , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
  • 8 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24 (03) 123-134
  • 9 Laffan MA, Lester W, O'Donnell JS. , et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (04) 453-465
  • 10 James PD, Lillicrap D. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. Am J Hematol 2012; 87 (Suppl. 01) S4-S11
  • 11 Mannucci PM, Franchini M, Castaman G, Federici AB. ; Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7 (02) 117-126
  • 12 Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97 (07) 1915-1919
  • 13 Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351 (07) 683-694
  • 14 Curnow J, Pasalic L, Favaloro EJ. Treatment of von Willebrand disease. Semin Thromb Hemost 2016; 42 (02) 133-146
  • 15 Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001; 14 (02) 365-379
  • 16 Federici AB, James P. Current management of patients with severe von Willebrand disease type 3: a 2012 update. Acta Haematol 2012; 128 (02) 88-99
  • 17 James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood 2013; 122 (05) 636-640
  • 18 Baaij M, van Galen KPM, Urbanus RT, Nigten J, Eikenboom JHC, Schutgens REG. First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. Br J Haematol 2015; 171 (03) 424-427
  • 19 Sarji KE, Stratton RD, Wagner RH, Brinkhous KM. Nature of von Willebrand factor: a new assay and a specific inhibitor. Proc Natl Acad Sci U S A 1974; 71 (08) 2937-2941
  • 20 Stratton RD, Wagner RH, Webster WP, Brinkhous KM. Antibody nature of circulating inhibitor of plasma von Willebrand factor. Proc Natl Acad Sci U S A 1975; 72 (10) 4167-4171
  • 21 Egberg N, Blombäck M. On the characterization of acquired inhibitors to ristocetin induced platelet aggregation found in patients with von Willebrand's disease. Thromb Res 1976; 9 (05) 527-531
  • 22 Mannucci PM, Meyer D, Ruggeri ZM, Koutts J, Ciavarella N, Lavergne JM. Precipitating antibodies in von Willebrand's disease. Nature 1976; 262 (5564): 141-142
  • 23 Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79 (05) 1459-1465
  • 24 James PD, Lillicrap D. The molecular characterization of von Willebrand disease: good in parts. Br J Haematol 2013; 161 (02) 166-176
  • 25 Zhang ZP, Lindstedt M, Falk G, Blombäck M, Egberg N, Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet 1992; 51 (04) 850-858
  • 26 Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol 2016; 9 (09) 825-830
  • 27 Favaloro EJ. Towards personalised therapy for von Willebrand disease: a future role for recombinant products. Blood Transfus 2016; 14 (02) 262-276
  • 28 Stewart MW, Etches WS, Shaw AR, Gordon PA. vWf inhibitor detection by competitive ELISA. J Immunol Methods 1997; 200 (1-2): 113-119
  • 29 Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 2003; 9 (03) 303-308
  • 30 Tout H, Obert B, Houllier A. , et al. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Thromb Haemost 2000; 83 (02) 274-281
  • 31 López-Fernández MF, Martin R, López-Berges C, Ramos F, Bosch N, Batlle J. Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease. Blood 1988; 72 (01) 116-120
  • 32 Mannucci PM, Tamaro G, Narchi G. , et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol 1987; 39 (05) 467-470
  • 33 Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125 (03) 348-355
  • 34 Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol 1995; 386: 87-92
  • 35 Franchini M, Lippi G, Montagnana M. , et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis 2009; 20 (04) 225-229
  • 36 Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD, Mowbray JF. Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. Blood 1981; 57 (01) 25-31
  • 37 Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost 2003; 1 (01) 190-192
  • 38 Franchini M, Gandini G, Giuffrida A, De Gironcoli M, Federici AB. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia 2008; 14 (03) 645-646
  • 39 Pergantou H, Xafaki P, Adamtziki E, Koletsi P, Komitopoulou A, Platokouki H. The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor. Haemophilia 2012; 18 (03) e66-e67
  • 40 Mannucci PM, Franchini M. Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease. Haemophilia 2017; 23 (02) 182-187
  • 41 Mannucci PM, Franchini M. Von Willebrand's disease. N Engl J Med 2017; 376 (07) 701
  • 42 Franchini M, Veneri D, Lippi G. The use of recombinant activated factor VII in congenital and acquired von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17 (08) 615-619
  • 43 Sucker C, Scharf RE, Zotz RB. Use of recombinant factor VIIa in inherited and acquired von Willebrand disease. Clin Appl Thromb Hemost 2009; 15 (01) 27-31
  • 44 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39 (07) 772-778
  • 45 Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26 (Suppl. 01) 150-154
  • 46 Grossmann RE, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000; 83 (04) 633-634
  • 47 Mannucci PM. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A 1995; 92 (07) 2428-2432